‌

US Patent 11535621 Heterobicyclic amides as inhibitors of CD38

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Ribon Therapeutics

Current Assignee

Ribon Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11535621

Date of Patent

December 27, 2022

Patent Application Number

16942857

Date Filed

July 30, 2020

Patent Primary Examiner

CPC Code

The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11535621 Heterobicyclic amides as inhibitors of CD38

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API